Cognify Therapeutics raises $95M to launch AI-powered drug target discovery suite

AI · 4 min read

Led by Helios BioVentures, the funding supports commercialization and regulatory validation of Cognify’s discovery suite. The company claims its models reduce the typical target discovery timeline by 30-40% by ranking high-confidence targets and suggesting validation experiments.

Cognify’s SaaS offers integration with lab automation systems and publishes explainability reports that detail feature importance across datasets. Early collaborators include a mid-size pharma that used the platform to identify two novel targets in metabolic disease programs.

Cognify plans to offer a private-cloud deployment for sensitive datasets and to expand support for single-cell and spatial transcriptomics. The company also announced grants for academic groups to test the platform on underfunded disease areas.